C

Capricor Therapeutics
D

CAPR

10.090
USD
0.14
(1.41%)
مغلق
حجم التداول
24,784
الربح لكل سهم
-0
العائد الربحي
-
P/E
-7
حجم السوق
461,191,894
أصول ذات صلة
A
ADAP
0.01110
(4.62%)
0.25130 USD
A
ARWR
-0.120
(-0.71%)
16.790 USD
C
CRIS
0.06000
(3.47%)
1.79000 USD
I
INO
-0.71500
(-33.49%)
1.42000 USD
K
KURA
0.04000
(0.69%)
5.85000 USD
O
OCUL
0.16500
(1.75%)
9.61000 USD
V
VCEL
0.130
(0.31%)
41.600 USD
المزيد
الأخبار المقالات

العنوان: Capricor Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.